Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Strides Arcolab — Merger or Acquisition (September 2014)
17 slides from Strides Pharma Science's merger presentation, Sep 30, 2014
Slide 1: Strides and Shasun Combining to Accelerate Strategy and Growth
Strides and Shasun Combining to Accelerate Strategy and Growth Analyst Presentation 30th September 2014
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by Strides Arcolab Limited (the "Company"), has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendatio
Slide 3: Transaction Overview
Transaction Overview On Monday, 29 September 2014, the boards of Strides Arcolab Limited (“Strides”) and Shasun Pharmaceuticals Limited (“Shasun”) approved the Scheme of Arrangement (“Scheme of Arrangement”) for the merger of the two Companies Combination to create a vertically integrated pharma com
Slide 4: Proposed Transaction Terms
Proposed Transaction Terms Surviving Entity: Strides Arcolab Limited (“Strides”, the “ Company”) Scheme of arrangement pursuant to the Companies Act 1956 and the Structure: Companies Act 2013 100% share for share exchange; merger via scheme of arrangement pursuant to Consideration: the Companies Act
Slide 5: Overview of Shasun
Overview of Shasun Overview of Shasun Revenue (INR million) Founded in 1976, Shasun is headquartered in Chennai, India and listed on the Bombay Stock Exchange and the National Stock Exchange of India 15,000 12,349 11,058 11,010 Develops, manufactures and sells API and FDF primarily for the regulated
Slide 6: Strategic Rationale of the Merger
Strategic Rationale of the Merger 1 Creates a vertically integrated pharma company of scale with strong presence in front ended regulated market FDF, emerging markets branded generics, institutional business, APIs and CRAMS 2 Significantly enhanced regulated market FDF portfolio in Rx and OTC in nic
Slide 7: Vertically Integrated Merged Entity with Diversified Revenue Streams across Geographies
1 Vertically Integrated Merged Entity with Diversified Revenue Streams across Geographies Merged Entity had revenues of INR 24,795 million and EBITDA of INR 3,784 million of June 30, 2014 LTM Revenue Strides – INR 11,704 million Shasun – INR 13,091 million Merged Entity – INR 24,795 million (June 20
Slide 8: Enhanced Regulated Market FDF Portfolio in Niche and Complex Segments
2 Enhanced Regulated Market FDF Portfolio in Niche and Complex Segments Enhanced Regulated Market FDF Portfolio and Access to Pipeline of Complex Extended Release Products USFDA Approved Filed Pipeline Total Filing 2015 Launched Partnered SGC 2 5 1 8 - 2 - Extended - 2 32 34 1 - 13 Release Creams an
Slide 9: Strengthened Institutional Business via Vertical Integration Benefits
3 Strengthened Institutional Business via Vertical Integration Benefits Strides Current Positioning Shasun Strengthens the Group’s Position Develops and manufactures antiretroviral and anti-malaria World Health Organisation (“WHO”) and US FDA approved medicines FDF facilities with spare capacity and
Slide 10: Leverage In-house API Capabilities
3 Leverage In-house API Capabilities Overview of DMF Filings 50 43 40 30 23 20 10 0 DMFs Commercialised DMFs Under Development Portfolio of 43 commercialised DMFs and an additional 23 DMFs under development Merged entity to leverage Shasun’s best in class API manufacturing capacities and align focus
Slide 11: De-risked Business Model with Significantly Enhanced Operational Infrastructure of Scale
4 De-risked Business Model with Significantly Enhanced Operational Infrastructure of Scale Strides Shasun Merged Entity Formulation Development 110 106 216 R&D Scientists Process Chemistry R&D - 187 187 Scientists Manufacturing and Other c.1,500 c.2,100 c.3,600 Employees FDF Facilities – US FDA 2 1
Slide 12: Catapults Merged Entity to Amongst the Top Listed Indian Pharma Companies by Revenue
5 Catapults Merged Entity to Amongst the Top 15 Listed Indian Pharma Companies by Revenue Sun Pharma + Ranbaxy 2,70,732 Dr. Reddy's Laboratories 1,38,897 Lupin 1,21,512 Cipla 1,03,820 Aurobindo Pharma 92,953 Cadila Healthcare 76,371 Glenmark Pharmaceuticals 62,556 Jubilant Life Sciences Limited 59,1
Slide 13: Significant Scope for Synergies Leading to Value Creation for All Stakeholders
6 Significant Scope for Synergies Leading to Value Creation for All Stakeholders Merged Entity to cross-leverage the existing relationships across API and regulated Revenue markets formulations business Synergies Benefit from large scale and wider geographic reach Synergies to be realised through wo
Slide 14: Post Merger Shareholding Structure
Post Merger Shareholding Structure Post Merger Shareholding Group Cross Holdings Structure1 SeQuent Scientific Limited owns 15.7 %(1) stake on a fully diluted basis in Shasun 34.1% This ownership is via the preferential allotment and 23.7% convertible warrants issued to SeQuent Scientific Limited on
Slide 15: Key Next Steps
Key Next Steps Announcement: September 29, 2014 Shareholder approval from both Strides and Shasun Approval from SEBI and Stock Exchange Court approval for Scheme of Arrangement FIPB Approval RBI Approval CCI Approval Closing: Anticipated by June 2015 15
Slide 16: Advisors to the Transaction
Advisors to the Transaction • Determination of the fair exchange • S.R. Batliboi & Co. LLP and Price Waterhouse ratio & Co. LLP • Fairness opinion to the board of • Jefferies India Private Limited Strides Arcolab Limited • Fairness opinion to the board of • IDFC Securities Limited Shasun Pharmaceuti
Slide 17: Thank You
- THANK YOU
Strides Arcolab — Merger or Acquisition (September 2014) on 6ix